SG10201908587PA - Treatment regimens - Google Patents
Treatment regimensInfo
- Publication number
- SG10201908587PA SG10201908587PA SG10201908587PA SG10201908587PA SG 10201908587P A SG10201908587P A SG 10201908587PA SG 10201908587P A SG10201908587P A SG 10201908587PA SG 10201908587P A SG10201908587P A SG 10201908587PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment regimens
- treatmentregimens
- npositions
- hsdd
- disorders
- Prior art date
Links
- 238000011269 treatment regimen Methods 0.000 title 1
- 206010024419 Libido decreased Diseases 0.000 abstract 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 abstract 2
- 208000017020 hypoactive sexual desire disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000036299 sexual function Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
TREATMENTREGIMENS The invention further relates to compounds, pharmaceutical co~npositions and methods for treating all disorders of human sexual function including hypoactive sexual desire disorder (HSDD) in a subject.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261679999P | 2012-08-06 | 2012-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201908587PA true SG10201908587PA (en) | 2019-10-30 |
Family
ID=50068530
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201500919PA SG11201500919PA (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
SG10201908587P SG10201908587PA (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
SG10201709967YA SG10201709967YA (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201500919PA SG11201500919PA (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201709967YA SG10201709967YA (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
Country Status (15)
Country | Link |
---|---|
US (1) | US9517254B2 (en) |
EP (1) | EP2879680A4 (en) |
JP (2) | JP2015524474A (en) |
KR (3) | KR20230136142A (en) |
CN (2) | CN106924259A (en) |
AU (2) | AU2013299725A1 (en) |
BR (1) | BR112015002687A2 (en) |
CA (1) | CA2881388A1 (en) |
EA (1) | EA201590349A1 (en) |
HK (2) | HK1211239A1 (en) |
IL (1) | IL237150B (en) |
MX (1) | MX2015001695A (en) |
SG (3) | SG11201500919PA (en) |
WO (1) | WO2014025814A1 (en) |
ZA (1) | ZA201501562B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170142797A (en) * | 2016-06-17 | 2017-12-28 | 에스원 바이오파머, 인크. | Methods of Treating Women for Hypoactive Sexual Desire Disorder (HSDD) with Bupropion and Trazodone Combination Treatment |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687771A (en) * | 1985-11-01 | 1987-08-18 | Bristol-Myers Company | Method for treatment of male impotence |
DE4321965A1 (en) * | 1993-07-01 | 1995-01-12 | Cytech Biomedical Inc | Oxytocin-containing composition and the use thereof as remedy, in particular nasal spray for the treatment of sexual dysfunctions |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
JP2002322085A (en) * | 2001-04-26 | 2002-11-08 | Kazuhito Tomizawa | Intelligent dysfunction therapeutic agent |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US9662371B2 (en) * | 2002-10-03 | 2017-05-30 | Neuropharmacology Services, Llc | Treatment of autism and similar disorders |
WO2004078147A2 (en) * | 2003-03-05 | 2004-09-16 | Pr Pharmaceuticals | Oxytocin controlled release formulations and methods of using same |
CN1946404A (en) * | 2004-04-22 | 2007-04-11 | 贝林格尔·英格海姆国际有限公司 | Pharmaceutical compositions for the treatment of sexual disorders II |
AU2005235422B2 (en) * | 2004-04-22 | 2011-08-11 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders II |
US20060004076A1 (en) | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
EP1827450A4 (en) | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | Methods for reducing the side effects associated with mirtazapine treatment |
US20060211685A1 (en) | 2005-03-04 | 2006-09-21 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
WO2008054984A1 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica, N.V. | Treatment of pervasive developmental disorders |
WO2008075162A2 (en) | 2006-12-15 | 2008-06-26 | Pfizer Limited | Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction |
WO2009016488A2 (en) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd. | Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods |
JP2012500801A (en) * | 2008-08-21 | 2012-01-12 | リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ | CNS disease treatment |
ES2731228T3 (en) * | 2009-01-20 | 2019-11-14 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Benzoic acid or salts thereof to improve the activity of a pharmaceutical product |
WO2011140608A1 (en) * | 2010-05-14 | 2011-11-17 | Keating Charlotte L | Neuropsychopharmacological treatment regimes for treating psychological disorders |
WO2011146726A1 (en) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders |
WO2012016229A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
KR101893551B1 (en) * | 2011-04-04 | 2018-08-30 | 에스원 바이오파머, 인크. | Treatment regimens |
-
2013
- 2013-08-06 SG SG11201500919PA patent/SG11201500919PA/en unknown
- 2013-08-06 US US14/420,112 patent/US9517254B2/en active Active
- 2013-08-06 WO PCT/US2013/053843 patent/WO2014025814A1/en active Application Filing
- 2013-08-06 EP EP13827390.9A patent/EP2879680A4/en not_active Withdrawn
- 2013-08-06 KR KR1020237027646A patent/KR20230136142A/en not_active Application Discontinuation
- 2013-08-06 KR KR1020157006024A patent/KR20150063039A/en not_active Application Discontinuation
- 2013-08-06 CA CA2881388A patent/CA2881388A1/en not_active Abandoned
- 2013-08-06 JP JP2015526649A patent/JP2015524474A/en not_active Ceased
- 2013-08-06 CN CN201710010422.0A patent/CN106924259A/en active Pending
- 2013-08-06 CN CN201380052215.1A patent/CN104884060A/en active Pending
- 2013-08-06 AU AU2013299725A patent/AU2013299725A1/en not_active Abandoned
- 2013-08-06 KR KR1020207031031A patent/KR20200128437A/en not_active Application Discontinuation
- 2013-08-06 BR BR112015002687A patent/BR112015002687A2/en not_active IP Right Cessation
- 2013-08-06 MX MX2015001695A patent/MX2015001695A/en unknown
- 2013-08-06 EA EA201590349A patent/EA201590349A1/en unknown
- 2013-08-06 SG SG10201908587P patent/SG10201908587PA/en unknown
- 2013-08-06 SG SG10201709967YA patent/SG10201709967YA/en unknown
-
2015
- 2015-02-08 IL IL237150A patent/IL237150B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01562A patent/ZA201501562B/en unknown
- 2015-12-10 HK HK15112183.5A patent/HK1211239A1/en unknown
-
2016
- 2016-03-01 HK HK16102368.2A patent/HK1214505A1/en unknown
-
2018
- 2018-05-30 JP JP2018103554A patent/JP2018150357A/en active Pending
- 2018-07-11 AU AU2018205121A patent/AU2018205121A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA201501562B (en) | 2017-11-29 |
CN106924259A (en) | 2017-07-07 |
HK1211239A1 (en) | 2016-05-20 |
KR20200128437A (en) | 2020-11-12 |
SG10201709967YA (en) | 2018-01-30 |
EP2879680A1 (en) | 2015-06-10 |
KR20230136142A (en) | 2023-09-26 |
JP2015524474A (en) | 2015-08-24 |
IL237150B (en) | 2018-07-31 |
IL237150A0 (en) | 2015-04-30 |
SG11201500919PA (en) | 2015-04-29 |
CN104884060A (en) | 2015-09-02 |
US9517254B2 (en) | 2016-12-13 |
US20150150946A1 (en) | 2015-06-04 |
KR20150063039A (en) | 2015-06-08 |
HK1214505A1 (en) | 2016-07-29 |
AU2013299725A1 (en) | 2015-03-26 |
WO2014025814A1 (en) | 2014-02-13 |
EP2879680A4 (en) | 2016-06-01 |
EA201590349A1 (en) | 2015-07-30 |
CA2881388A1 (en) | 2014-02-13 |
JP2018150357A (en) | 2018-09-27 |
MX2015001695A (en) | 2015-09-28 |
AU2018205121A1 (en) | 2018-07-26 |
BR112015002687A2 (en) | 2019-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019009437A (en) | Treatment of myelosuppression. | |
PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
PH12015500525A1 (en) | Formulations of enzalutamide | |
MX2015002292A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist. | |
MX2018010548A (en) | Dll3 modulators and methods of use. | |
PH12014501844B1 (en) | Peptidomimetic macrocycles | |
SG11201504895TA (en) | Apparatus with elliptical movement for skin cleansing, stimulation and delivery of treatments | |
MX2015014438A (en) | Methods of using interleukin-10 for treating diseases and disorders. | |
MY168032A (en) | Warm-Cool Beauty Treatment Device | |
NZ723884A (en) | Methods of treating alzheimer’s disease | |
HK1215173A1 (en) | Methods of treating s. aureus-associated diseases | |
MX2019004364A (en) | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder. | |
MX2015009277A (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine. | |
GB2501670B (en) | Improvements in or relating to beauty, health, or therapeutic treatments | |
SG10201908587PA (en) | Treatment regimens | |
MX354989B (en) | Treatment regimens. | |
MX2016002307A (en) | Cancer treatment. | |
WO2014083432A3 (en) | Female intranasal testosterone gel for treating anorgasmia | |
MY184721A (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis | |
MX2015008454A (en) | Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders. | |
MX2019009243A (en) | Methods for treating or preventing asthma by administering an il-4r antagonist. |